Radiomics involves deep quantitative analysis of radiological images for structural and/or functional information. – It is a phenomic assessment of disease to understand lesion microstructure, microenvironment and molecular/cellular function. – In oncology, it helps us accurately classify, stratify and prognosticate tumors based on if, how and when they transform, infiltrate, involute or metastasize, – Utilizing radiomics in clinical trials is exploratory, and not an established end-point. – Integrating radiomics in an imaging-based clinical trials involves a streamlined workflow to handle large datasets, robust platforms to accommodate machine learning calculations, and seamless incorporation of derived insights into outcomes matrix.
The quantitative neuroradiology initiative framework: application to dementia
Dual-Energy CT for Suspected Radiographically Negative Wrist Fractures: A Prospective Diagnostic Test Accuracy Study
A Critical Appraisal of the Quality of 18F-FDG PET/CT Guidelines in Oncology using the AGREE II tool: A EuroAIM Initiative
PET/MR in Neuro-oncology: is it Ready for Prime-time?
Current Landscape of Imaging and the Potential Role for Artificial Intelligence in the Management of COVID-19
Performance of Machine Learning-Augmented Analysis of Radiomics for the Head and Neck Cancer Histopathological Diagnosis: A Systematic Review and Meta-Analysis
A Radiofrequency Treatment Pathway for Cluneal Nerve Disorders
Radiomics in Clinical Trials – The Rationale, Current Practices, and Future Considerations
Reporter Gene Imaging and its Role in Imaging-Based Drug Development.
This abstract presents how RGI can be used in drug development for pharmacodynamic and pharmacokinetic assessment of cellular, gene, oncolytic viral and immunotherapeutic approaches using MRI, PET, SPECT, Ultrasound, Bioluminescence and Fluoroscence. Some of the teaching points include further insight into RGI imaging probes that can be direct, indirect or activable; range from enzymes, protein receptors and cell membrane transporters and how RGI qualitatively and quantitatively assesses cell targeting, transfection, protein expression and intracellular processes.